Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 425 results for stroke

  1. Injection for more than a million people to help prevent heart attacks and strokes recommended

    People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.

  2. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  3. Microwave ablation for atrial fibrillation in association with other cardiac surgery (HTG73)

    Evidence-based recommendations on microwave ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat produced from microwave energy to interrupt abnormal electrical signals.

  4. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  5. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

  6. Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (HTG286)

    Evidence-based recommendations on percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation. This involves using a probe attached to a balloon catheter to freeze tissue in one of the chambers on the left side of the heart.

  7. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

  8. Physical activity: for NHS staff, patients and carers (QS84)

    This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.

  9. Endoscopic transsphenoidal pituitary adenoma resection (HTG14)

    Evidence-based recommendations on endoscopic transsphenoidal pituitary adenoma resection. This involves inserting a tube into the nostril towards the tumour base and removing the tumour using specialised surgical instruments.

  10. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

  11. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  12. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  13. Disease-specific reference case extension: management of overweight and obesity in adults (PMG50)

    This NICE disease-specific reference case extension describes standardised methods for health economic evaluations of interventions for managing overweight and obesity in adults. For further details on developing and implementing disease-specific reference case extensions, see NICE’s position statement on use of disease-specific reference models in economic evaluations

  14. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.